Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Withdrawn) A method of eliciting or inducing, in a mammal, an immune response directed to a micro-organism said method comprising administering to said mammal an effective amount of an immunogenic composition which composition comprises a molecule capable of inducing an immune response directed to the inositol glycan domain of a GPI but which molecule is substantially incapable of inducing an immune response directed to a lipidic domain of GPI.

2. (Withdrawn) A method according to claim 1 wherein said molecule is a modified GPI molecule or derivative or equivalent thereof and which modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipidic domain.

3. (Withdrawn) A method according to claim 2 wherein said modified GPI molecule is the inositolglycan domain portion of GPI or derivative or equivalent thereof.

4. (Withdrawn) A method according to claim 2, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

5. (Withdrawn) A method according to claim 4 wherein said parasite is *Plasmodium*.

6. (Withdrawn) A method according to claim 5 wherein said *Plasmodium* is *Plasmodium falciparum*.

7. (Withdrawn) A method according to claim 6 wherein said modified *Plasmodium falciparum* GPI molecule is a *Plasmodium falciparum* GPI inositolglycan domain.

8. (Withdrawn) A method according to claim 7 wherein said GPI inositol glycan domain comprises the structure ethanolamine-phosphate-(Manα1,2)-

Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol or derivative or equivalent thereof.

9. (Withdrawn) A method according to claim 7 wherein said GPI inositol glycan domain comprises the structure X_1 - X_2 - X_3 -X_4 - ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol wherein X_1, X_2, X_3 and X_4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

10. (Withdrawn) A method according to claim 7 wherein said GPI inositolglycan domain comprises a structure selected from:

EtN-P-[Mα2]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][X]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4Gα6Ino

EtN-P-Mα2 Mα6 Mα4G

Mα2 Mα6 Mα4G

EtN-P-Mα2 Mα6 M

EtN-P-[Mα2][G]Mα2 Mα6 Mα4G

EtN-P-[Mα2][X]Mα2 Mα6 Mα4G

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4G

Mα2 [Mα2][G]Mα2 Mα6 Mα4G

Mα2 [Mα2][X]Mα2 Mα6 Mα4G

Mα2 [Mα2][EtN-P]Mα6 Mα4G

Mα6 Mα4Gα6Ino

Mα2 Mα6 Mα4Gα6Ino

Mα2 [Mα2]Mα6 Mα4Gα6Ino

Mα2 [Mα2][G]Mα6 Mα4Gα6Ino

Mα2 [Mα2][X]Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 M

EtN-P-[Mα2][X]Mα2 Mα6 M

EtN-P-[Mα2][EtN-P]Mα2 Mα6 M

Mα2 [Mα2][G]Mα2 Mα6 M

Mα2 [Mα2][X]Mα2 Mα6 M

Mα2 [Mα2][EtN-P]Mα6 M

Mα2 Mα6 M

Mα6 Mα4G

EtN-P-[Mα2][G]Mα2 M

EtN-P-[Mα2][X]Mα2 M

EtN-P-[Mα2][EtN-P]Mα2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substituent, α represents α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.

11. (Withdrawn) A method of therapeutically or prophylactically treating a mammal for a micro-organism infection said method comprising administering to said mammal an effective amount of an immunogenic composition which composition comprises a molecule capable of inducing an immune response directed to the inositolglycan domain of a GPI, but substantially incapable of inducing an immune response directed to the lipid domain of a GPI, for a time and under conditions sufficient for said immune response to reduce, inhibit or otherwise alleviate any one or more symptoms associated with infection of said mammal by said micro-organism.

12. (Withdrawn) A method according to claim 11 wherein said molecule is a modified GPI molecule or derivative or equivalent thereof and which modified GPI molecule comprises insufficient lipid domain to induce or elicit an immune response directed to a GPI lipidic domain.

13. (Withdrawn) A method according to claim 12 wherein said micro-organism infection is a parasite infection.

14. (Withdrawn) A method according to claim 13 wherein said parasite is *Plasmodium*.

15. (Withdrawn) A method according to claim 14 wherein said *Plasmodium* is *Plasmodium falciparum*.

16. (Withdrawn) A method according to claim 13 wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

17. (Withdrawn) A method according to claim 16 wherein said parasite is *Plasmodium*.

18. (Withdrawn) A method according to claim 17 wherein a said *Plasmodium* is *Plasmodium falciparum*.

19. (Withdrawn) A method according to claim 18 wherein said modified *Plasmodium falciparum* GPI molecule is a *Plasmodium falciparum* GPI inositolglycan domain.

20. (Withdrawn) A method according to claim 19 wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol or derivative or equivalent thereof.

21. (Withdrawn) A method according to claim 19 wherein said GPI inositolglycan domain comprises the structure

X_1 - X_2 - X_3 -X_4 - ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol wherein X_1, X_2, X_3 and X_4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

22. (Withdrawn) A method according to claim 19 wherein said GPI inositolglycan domain comprises a structure selected from:

EtN-P-[Mα2]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][X]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4Gα6Ino

EtN-P-Mα2 Mα6 Mα4G

Mα2 Mα6 Mα4G

EtN-P-Mα2 Mα6 M

EtN-P-[Mα2][G]Mα2 Mα6 Mα4G

EtN-P-[Mα2][X]Mα2 Mα6 Mα4G

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4G

Mα2 [Mα2][G]Mα2 Mα6 Mα4G

Mα2 [Mα2][X]Mα2 Mα6 Mα4G

Mα2 [Mα2][EtN-P]Mα6 Mα4G

Mα6 Mα4Gα6Ino

Mα2 Mα6 Mα4Gα6Ino

Mα2 [Mα2]Mα6 Mα4Gα6Ino

Mα2 [Mα2][G]Mα6 Mα4Gα6Ino

Mα2 [Mα2][X]Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 M

EtN-P-[Mα2][X]Mα2 Mα6 M

EtN-P-[Mα2][EtN-P]Mα2 Mα6 M

Mα2 [Mα2][G]Mα2 Mα6 M

Mα2 [Mα2][X]Mα2 Mα6 M

Mα2 [Mα2][EtN-P]Mα6 M

Mα2 Mα6 M

Mα6 Mα4G

EtN-P-[Mα2][G]Mα2 M

EtN-P-[Mα2][X]Mα2 M

EtN-P-[Mα2][EtN-P]Mα2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substituent, α represents α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.

23. (Withdrawn) A method for the treatment and/or prophylaxis of a mammalian disease condition characterised by a micro-organism infection, said method comprising administering to said mammal an effective amount of an immunogenic composition which composition comprises a molecule capable of inducing an immune response directed to the inositolglycan domain of a GPI, but substantially incapable of inducing an immune response directed to the lipid domain of a GPI, for a time and under conditions sufficient for said immune response to reduce, inhibit or otherwise alleviate any one or more symptoms associated with said micro-organism infections.

24. (Withdrawn) A method according to claim 23 wherein said molecule is a modified GPI molecule or derivative or equivalent thereof and which modified GPI molecule comprises insufficient lipid domain to induce or elicit an immune response directed to a GPI lipidic domain.

25. (Withdrawn) A method according to claim 24 wherein said modified GPI molecule is the inositolglycan domain portion of GPI or derivative or equivalent thereof.

26. (Withdrawn) A method according to claim 24 wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

27. (Withdrawn) A method according to claim 26 wherein said parasite is *Plasmodium*.

28. (Withdrawn) A method according to claim 27 wherein said *Plasmodium* is *Plasmodium falciparum*.

29. (Withdrawn) A method according to claim 28 wherein said modified *Plasmodium falciparum* GPI molecule is a *Plasmodium falciparum* GPI inositolglycan domain.

30. (Withdrawn) A method according to claim 29 wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol or derivative or equivalent thereof.

31. (Withdrawn) A method according to claim 29 wherein said GPI inositolglycan domain comprises the structure X_1 - X_2 - X_3 -X_4 - ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol wherein X_1, X_2, X_3 and X_4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

32. (Withdrawn) A method according to claim 29 wherein said GPI inositolglycan domain comprises the structure:

EtN-P-[Mα2]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][X]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4Gα6Ino

EtN-P-Mα2 Mα6 Mα4G

Mα2 Mα6 Mα4G

EtN-P-Mα2 Mα6 M

EtN-P-[Mα2][G]Mα2 Mα6 Mα4G

EtN-P-[Mα2][X]Mα2 Mα6 Mα4G

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4G

Mα2 [Mα2][G]Mα2 Mα6 Mα4G

Mα2 [Mα2][X]Mα2 Mα6 Mα4G

Mα2 [Mα2][EtN-P]Mα6 Mα4G

Mα6 Mα4Gα6Ino

Mα2 Mα6 Mα4Gα6Ino

Mα2 [Mα2]Mα6 Mα4Gα6Ino

Mα2 [Mα2][G]Mα6 Mα4Gα6Ino

Mα2 [Mα2][X]Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 M

EtN-P-[Mα2][X]Mα2 Mα6 M

EtN-P-[Mα2][EtN-P]Mα2 Mα6 M

Mα2 [Mα2][G]Mα2 Mα6 M

Mα2 [Mα2][X]Mα2 Mα6 M

Mα2 [Mα2][EtN-P]Mα6 M

Mα2 Mα6 M

Mα6 Mα4G

EtN-P-[Mα2][G]Mα2 M

EtN-P-[Mα2][X]Mα2 M

EtN-P-[Mα2][EtN-P]Mα2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substituent, α represents α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.

33. (Withdrawn) A method according to claim 24, wherein said disease condition is malaria.

34. (Withdrawn) Use of a composition comprising a molecule capable of inducing an immune response directed to a micro-organism GPI inositolglycan domain but substantially incapable of inducing an immune response directed to a lipidic domain of GPI in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of a mammalian disease condition characterised by infection with said micro-organism.

35. (Withdrawn) A method according to claim 34 wherein said composition comprises a *Plasmodium* GPI inositolglycan domain or derivative or equivalent thereof which inositolglycan domain comprises insufficient lipidic domain of a *Plasmodium* GPI to elicit or induce an immune response directed to a GPI lipidic domain.

36. (Withdrawn) A composition capable of inducing an immune response directed to a micro-organism said composition comprising a molecule capable of inducing an immune response against a micro-organism GPI inositolglycan domain but substantially incapable of inducing an immune response to a lipidic domain of a GPI.

37. (Withdrawn) A composition according to claim 36 wherein said molecule comprises a modified GPI molecule or derivative or equivalent thereof which modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipidic domain.

38. (Previously presented) A composition comprising modified GPI molecule or derivative or equivalent thereof which induces an immune response directed to a micro-

organism GPI inositolglycan domain but is incapable of inducing an immune response directed to a lipidic domain of said GPI.

39. (Cancelled)

40. (Withdrawn) A pharmaceutical composition comprising a molecule capable of inducing an immune response directed to a micro-organism GPI inositolglycan domain but substantially incapable of inducing an immune response directed to a lipidic domain of a GPI together with one or more pharmaceutically acceptable carriers and/or diluents.

41. (Withdrawn) A pharmaceutical composition according to claim 40 wherein said molecule comprises a modified GPI molecule or derivative or equivalent thereof which modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipidic domain.

42. (Withdrawn) A composition according to claim 37 wherein said modified GPI molecule is the inositolglycan domain portion of GPI or a derivative or equivalent thereof.

43. (Withdrawn) A composition according to claim 37 wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

44. (Withdrawn) A composition according to claim 43 wherein said parasite is *Plasmodium*.

45. (Withdrawn) A composition according to claim 41 wherein said *Plasmodium* is *P.falciparum*.

46. (Withdrawn) A composition according to claim 42 wherein said modified *Plasmodium falciparum* GPI molecule is a *Plasmodium falciparum* GPI inositolglycan domain.

47. (Withdrawn) A composition according to claim 46 wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Manα1,2)-

Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol or derivative or equivalent thereof.

48. (Withdrawn) A composition according to claim 46 wherein said GPI inositolglycan domain comprises the structure X_1 - X_2 - X_3 -X_4 - ethanolamine-phosphate-(Manα1,2)-Manα1,2Manα1,6Manα1,4GlcN-*myo*-inositol phosphoglycerol wherein X_1, X_2, X_3 and X_4 are any 4 amino acids, or derivative or equivalent of said GPI inositolglycan domain.

49. (Withdrawn) A composition according to claim 46 wherein said GPI inositolglycan domain comprises the structure:

EtN-P-[Mα2]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][X]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4Gα6Ino

EtN-P-Mα2 Mα6 Mα4G

Mα2 Mα6 Mα4G

EtN-P-Mα2 Mα6 M

EtN-P-[Mα2][G]Mα2 Mα6 Mα4G

EtN-P-[Mα2][X]Mα2 Mα6 Mα4G

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4G

Mα2 [Mα2][G]Mα2 Mα6 Mα4G

Mα2 [Mα2][X]Mα2 Mα6 Mα4G

Mα2 [Mα2][EtN-P]Mα6 Mα4G

Mα6 Mα4Gα6Ino

Mα2 Mα6 Mα4Gα6Ino

Mα2 [Mα2]Mα6 Mα4Gα6Ino

Mα2 [Mα2][G]Mα6 Mα4Gα6Ino

Mα2 [Mα2][X]Mα6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 M

EtN-P-[Mα2][X]Mα2 Mα6 M

EtN-P-[Mα2][EtN-P]Mα2 Mα6 M

Mα2 [Mα2][G]Mα2 Mα6 M

Mα2 [Mα2][X]Mα2 Mα6 M

Mα2 [Mα2][EtN-P]Mα6 M

Mα2 Mα6 M

Mα6 Mα4G

EtN-P-[Mα2][G]Mα2 M

EtN-P-[Mα2][X]Mα2 M

EtN-P-[Mα2][EtN-P]Mα2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is mannose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, Ino is inositol or inositol-phosphoglycerol, [X] is any other substituent, α represents α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.

50. (Withdrawn) An antibody directed to a GPI inositolglycan domain but which antibody is substantially incapable of interacting with the lipidic domain of a GPI.

51. (Withdrawn) A pharmaceutical composition comprising an antibody directed to a GPI inositolglycan domain, but which antibody is substantially incapable of interacting with a GPI lipidic domain, together with one or more pharmaceutically acceptable carriers and/or diluents.

52. (Withdrawn) A method of inhibiting, halting or delaying the onset or progression of a mammalian disease condition characterised by a micro-organism infection, said method comprising administering to said mammal an effective amount of an antibody as claimed in claim 50.

53. (Cancelled)

54. (Previously presented) A composition according to claim 38, wherein said modified GPI molecule comprises insufficient lipidic domain to induce or elicit an immune response directed to a GPI lipid domain.

55. (Previously presented) A composition according to claim 38 or 54, wherein said modified GPI molecule is the inositolglycan domain portion of GPI or a derivative or equivalent thereof.

56. (Previously presented) A composition according to claim 55, wherein said modified GPI molecule is a modified parasite GPI molecule or derivative or equivalent thereof.

57. (Previously presented) A composition according to claim 56, wherein said parasite is Plasmodium.

58. (Previously presented) A composition according to claim 57, wherein said Plasmodium is *P. falciparurn.*

59. (Previously presented) A composition according to claim 54 or 58, wherein said GPI inositolglycan domain comprises the structure ethanolamine-phosphate-(Manα 1 ,2)-Manα 1 ,2Manα 1 ,6Manα 1 ,4G1cN-myo-inositol phosphoglycerol or a derivative or equivalent thereof.

60. (Previously presented) A composition according to claim 54 or 58, wherein said GPI inositolglycan domain comprises the structure

X1 — X2 — X3 — X4 — ethanolamine-phosphate-(Manαl,2)-Manαl, 2Manαl, 6Manαl, 4GIcN-myo-inositol phosphoglycerol

wherein X1, X2, X3 and X4 are any 4 amino acids, or derivative or equivalent of said GPI inositoiglycan domain.

61. (Previously presented) A composition according to claim 54 or 58, wherein said GPI inositolglycan domain comprises the structure

EtN-P-[Mα 2]Mα2 Mα 6 Mα4Gα6Ino

EtN-P-[Mα2][G]Mα2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2][X]Mc~2 Mα6 Mα4Gα6Ino

EtN-P-[Mα2] [EtN-P]Mα2 Mct6 Mα4Gu6Ino

EtN-P-Mα2 Mα6 Mα4G

Mα2 Mα6 Mα4G

EtN-P-Mα2 Mα6 M

EtN-P-[Mo~2]{G]Mα2 Mα6 Mα4G

EtN-P-{Mα2][X]Mα2 Mα6 Mα4G

EtN-P-[Mα2][EtN-P]Mα2 Mα6 Mα4G

Mα2 [Mα2][G]Mα2 Mα6 Mα4G

Mα2 [Mx2][X]Mα2 Mα6 Mα4G

Mα2 [Mα2][EtN-P]Mα6 Mα4G

Mα6 Mx4Gα6Ino

Mcx2 Mα6 Mα4Gu6Ino

Mα2 {Mα2]Mα6 Mα4Gα6Ino

Mci2 [Mα2][G]Mci6 Mα4Gα6Ino

Mα2 [Mα2][X]Mα6 Mα4Gα6Ino

EtN-P-[Mα2][GJMα2 Mα6 M

EtN-P-[Mα2][X]Mα2 Mu6 M

EtN-P-[Mct2] [EtN-P]Mα2 Mα6 M

Mα2 [Mα2][G]Mα2 Mcz6 M

Mα2 [Mα2][X]Mα2 Mα6 M

Mα2 [Mα2]{EtN-P]Mα6 M

Mα2 Mα6 M

Mα6 Mα4G

EtN-P-[Mα2] [G]Mα2 M

EtN-P-[Mu2][XJMcx2 M

EtN-P-[Mα2] [EtN-P]Mi2 M

or derivative or equivalent thereof wherein EtN is ethanolamine, P is phosphate, M is marmose, G is non-N-acetylated glucosamine, [G] is any non-N-acetylated hexosamine, mo is inositol or inositol-phosphoglycerol, [X] is any other substitute, α represent α-linkages which may be substituted with β-linkages wherever required, and numeric values represent positional linkages which may be substituted with any other positional linkages as required.